Side-by-side comparison of AI visibility scores, market position, and capabilities
Plymouth MN phosphate and potash fertilizer (NYSE: MOS) ~$11.2B FY2024 revenue; largest US phosphate producer, Saskatchewan potash, Brazil distribution, post-2022 price normalization competing with Nutrien and OCP.
The Mosaic Company is a Plymouth, Minnesota-based fertilizer company — publicly traded on the New York Stock Exchange (NYSE: MOS) as an S&P 500 Materials component — producing and selling potash (potassium-based fertilizer mined from underground ore deposits) and phosphate (phosphate rock mining and processing into diammonium phosphate, monoammonium phosphate, and triple superphosphate fertilizers) critical for global agricultural production through approximately 13,000 employees. Mosaic is the largest US producer of concentrated phosphate and potash and one of the largest producers globally, with phosphate mining operations in Florida and North Carolina (mines at Wingate Creek, South Fort Meade, and Four Corners) and Canada (Saskatchewan potash mines at Esterhazy, Belle Plaine, and Colonsay), and operations in Brazil (mining and blending), Australia, and internationally. In fiscal year 2024, Mosaic reported revenues of approximately $11.2 billion and adjusted EBITDA of approximately $2.5 billion, navigating potash price normalization from the extraordinary 2022 spike ($1,000/metric ton potash following Russia and Belarus sanctions that disrupted 40% of global potash supply — driving prices up 4x from 2021 baseline) down to $200-250/MT range by late 2024 as Belarusian potash found alternative export routes through Russia and Chinese ports. CEO Bruce Bodine, appointed in 2023 after Joc O'Rourke's retirement, focuses Mosaic's strategy on operational efficiency and Brazilian market expansion as price normalization compresses margins versus the 2022 supercycle that generated exceptional profitability.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.